Please check your internet connection and try again.
# Sodium Phosphate Enema
## Overview
Sodium phosphate enemas are hypertonic saline laxatives that draw fluid into the lumen of the colon, inducing peristalsis and evacuation. They typically act within 2 to 15 minutes.
## Primary Indications
* Relief of occasional constipation.
* Bowel cleansing prior to rectal examinations or endoscopic procedures.
## Adult Dosing
* **Standard dose:** 118 mL (one ready-to-use bottle) administered rectally as a single dose. Do not exceed one dose in 24 hours.
## Pediatric Dosing
* **Children 2–11 years:** 59 mL (pediatric size) administered rectally as a single dose. Do not exceed one dose in 24 hours.
* **Children <2 years:** Use is contraindicated due to high risk of severe electrolyte disturbances.
## Dose Adjustments
* **Renal Impairment:** Use with extreme caution. Severe hyperphosphatemia and hypocalcemia can occur rapidly, particularly in patients with pre-existing renal disease.
* **Hepatic Impairment:** No formal dosage adjustments, but monitor for fluid/electrolyte imbalances.
## Contraindications
* Hypersensitivity to sodium phosphates.
* Congestive heart failure.
* Clinically significant renal impairment (e.g., end-stage renal disease).
* Megacolon, bowel obstruction, or perforation.
* Undiagnosed abdominal pain or symptoms of appendicitis.
* Patients <2 years of age.
## Adverse Effects
* **Electrolyte disturbances:** Hyperphosphatemia, hypocalcemia, hypernatremia, hypokalemia.
* **Gastrointestinal:** Abdominal pain, cramping, nausea, vomiting, rectal irritation, or mucosal injury.
* **Serious:** Acute phosphate nephropathy (calcium phosphate deposits in renal tubules), arrhythmia (secondary to electrolyte shifts), seizure, or hypotension.
## Key Drug Interactions
* **Diuretics:** Increased risk of dehydration and electrolyte imbalances.
* **Nephrotoxic agents:** Concurrent use (e.g., NSAIDs, ACE inhibitors) increases risk of acute kidney injury.
* **Calcium Channel Blockers:** Potential for additive effects on electrolyte levels.
## Monitoring
* Serum electrolytes (calcium, phosphate, potassium, sodium).
* Renal function (BUN/Creatinine).
* Hydration status.
* Monitor for signs of hypocalcemia (tetany, paresthesias, ECG changes).
## Clinical Pearls
* **Patient Position:** Patients should be positioned in the left lateral decubitus position (Sims' position) for administration.
* **Forced Administration Warning:** Never force the enema tip into the rectum, as this can cause perforation.
* **Hydration:** Strongly encourage the patient to drink a full glass (8 oz) of clear liquid after administration to prevent dehydration.
* **Safety Risk:** Sodium phosphate products have been associated with rare but permanent renal damage; avoid use in patients with bowel obstruction or those who cannot maintain adequate fluid intake.
***
*Disclaimer: This information is for educational purposes only. Clinical guidelines and prescribing information change frequently. Always verify the most current prescribing information, renal dosing protocols, and facility-specific policies before clinical use.*
